Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Appointment of Non-executive Director

27th Nov 2017 07:00

RNS Number : 5273X
BTG PLC
27 November 2017
 

 

BTG plc: Appointment of Non-executive Director

 

London, UK, 27 November 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today announces the appointment of Gregory Barrett as a non-executive director of the Board.

 

Greg has a broad range of commercial experience in the US medtech industry, with a focus on interventional medicine therapies. He is currently a non-executive director of Cutera Inc and was previously President and Chief Executive Officer of DFINE Inc, Barrx Medical Inc, and ACMI Corporation. Prior roles include leading a minimally invasive surgery division of Boston Scientific, both in US and in emerging markets. Greg has also held a series of senior sales and marketing roles at a number of companies including Baxter Healthcare and C.R. Bard.

 

Garry Watts, BTG's Chairman, commented: "Greg brings a strong track record to BTG, with significant US commercial and international medtech experience, which will be of great benefit to us as we continue to implement our growth plans."

 

There are no further details to be disclosed in relation to paragraph 9.6.13R of the Financial Conduct Authority Listing Rules.

 

For further information contact:

 

BTG

Andy Burrows, VP Corporate & Investor Relations

+44 (0)20 7575 1741; Mobile: +44 (0)7990 530 605

 

Stuart Hunt, Investor Relations Manager

+44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536

 

Chris Sampson, Corporate Communications Director

+44 (0)20 7575 1595; Mobile: +44 (0)7773 251 178

 

FTI Consulting

Ben Atwell/Simon Conway

+44 (0)20 3727 1000

 

About BTG

BTG is a global specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of cancer, severe emphysema, severe blood clots and varicose veins, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today's most complex healthcare challenges. To learn more about BTG, please visit: btgplc.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOALLFSDLVLRFID

Related Shares:

BTG
FTSE 100 Latest
Value8,494.85
Change31.39